Lopinavir/ritonavir + zidovudine + lamivudine ( DrugBank: Zidovudine, Ritonavir, Lamivudine, Lopinavir )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 265 | 脂肪萎縮症 | 1 |
265. 脂肪萎縮症
臨床試験数 : 116 / 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00122226 (ClinicalTrials.gov) | January 2003 | 14/7/2005 | MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) | MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) | HIV Infections;HIV-Associated Lipodystrophy Syndrome | Drug: Lopinavir/ritonavir + zidovudine + lamivudine;Drug: Lopinavir/ritonavir + nevirapine | VU University Medical Center | Abbott;Boehringer Ingelheim | Active, not recruiting | 18 Years | 70 Years | Male | 50 | Phase 4 | Finland;Netherlands;Spain;United Kingdom |